AMAM News and Press, Ambrx Biopharma Inc. American Depositary Shares (each representing seven) From 05/11/23

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced that Daniel J. O’Connor, Chief Executive Officer and President of Ambrx, will present a corporate overview at the JMP Securities Life Sciences Conference and RBC Capital Markets Globa...

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), today announced the appointment of Andrew P. Aromando as Chief Operating Officer. Mr. Aromando brings over 30 years of experience across numerous functional areas in the biopharmaceutical industry, serving ...

SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), announced new preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, held from April 14 to 19, 2023. Ambrx’s presentations highlight ...

2023-03-30 18:04:08 ET Ambrx Biopharma ( AMAM ) disclosed in a Securities and Exchange filing on Thursday an offering of its shares to raise up to $300 million. The company expects to offer and sell its ordinary shares, and its American Depositary Shares representing the ordinary ...

SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx (NASDAQ: AMAM), announced the presentation of three posters featuring preclinical data at the upcoming 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, from April 14 to 19, 2023. T...

2023-03-24 17:28:03 ET Gainers: BridgeBio Pharma ( BBIO ) +14% . Iovance Biotherapeutics ( IOVA ) +10% . Iris Energy  ( IREN ) +5% . Alphabet ( GOOGL ) +4% . Zions Bancorporation  ( ZION ) +3% . Losers: CRISPR T...

Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), today announced that it has completed net sales of approximately $78 million of American Depositary Shares (“ADSs”) pursuant to the Company’s at-the-market (“ATM”) program established on Aug 5, 2022, through Cowen and...

2023-03-13 00:55:00 ET Summary Sino Biopharm was approved to close its $161 million all-cash acquisition of F-star, a Cambridge, UK company that develops bispecific antibodies. Harbour BioMed announced positive results from a China Phase III trial of its anti-FcRn mAb in patients ...

2023-03-07 15:32:17 ET Shares of Ambrx BioPharma (NYSE: AMAM) fell 28.1% for the day as of late Tuesday afternoon. The clinical-stage biotech announced Monday that it was moving from trading on the New York Stock Exchange to the Nasdaq Stock Market, effective March 16. When ...

2023-03-07 12:39:41 ET Gainers: ThredUp ( TDUP ) +73% . WW International ( WW ) +49% . Unicycive ( UNCY ) +39% . Protagonist Therapeutics ( PTGX ) +32% . Bionomics ( BNOX ) +28% . Novo Integrated Sciences ( NVOS ) +25% ...